For targeting oxidative stress, the clinical trial of Nrf2 activators, such as sulforaphane, bardoxolone methyl (CDDO; 1[2-cyano-3,12-dioxooleana-1,9(11)-dien 28-oyl] or dimethyl fumarate (BG-12) is currently a selective drugs that act on the phosphoinositide 3-kinase δ-subunit (PI3Kδ)-histone deacetylase 2 (HDAC2) pathway leading to defective Nrf2 function in COPD lack specificity (Sussan et al., 2009; Mercado et al., 2011; Gold et al., 2012). The gene discussed is NFE2L2; the disease is chronic obstructive pulmonary disease.